ExeVir and Mithra announce manufacturing collaboration for innovative Covid-19 treatments
Accelerated clinical development of ExeVir s novel llama-derived antibody therapies for potential treatment and prevention of Covid-19
-
-
Joint unique expertise of two Belgian biotechs to provide global access to innovative therapies for a broad range of coronaviruses, including variants of concern
GHENT, Belgium, July 15, 2021 /PRNewswire/ ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, and Mithra Pharmaceuticals (Euronext Brussels: MITRA) announce a new collaboration to utilize the fill and finish capabilities for ExeVir s innovative therapies at Mithra s integrated R&D and manufacturing platform, Mithra CDMO.